INTEGRIS-IPF: A 12-Week, Phase 2a Study Evaluating the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants with Idiopathic Pulmonary Fibrosis | Zendy

AI Assistant Blog Pricing

INTEGRIS-IPF: A 12-Week, Phase 2a Study Evaluating the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants with Idiopathic Pulmonary Fibrosis

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.